Compositions comprising oxo-derivatives of fatty acids and methods of making and using same
The present disclosure provides 15-oxo-EPA and 15-oxo-DGLA, compositions comprising 15-oxo-EPA and/or 15-oxo-DGLA, and methods of treating and/or preventing fibrosis, skin disorders, inflammation, kidney disease or renal dysfunction in a subject in need thereof by administering 15-oxo-EPA and/or 15-oxo-DGLA.
1. (5Z,8Z,11Z,13E,17Z)-15-oxoicosa-5,8,11,13,17-pentaenoic acid.
2. A composition comprising (5Z,8Z,11Z,13E,17Z)-15-oxoicosa-5,8,11,13,17-pentaenoic acid.
3. (8Z,11Z,13E)-15-oxoicosa-8,11,13-trienoic acid.
4. A composition comprising (8Z,11Z,13E)-15-oxoicosa-8,11,13-trienoic acid.
5. The composition of claim 2 , wherein the composition is a pharmaceutical composition comprising about 0.1 g to about 4 g of (5Z,8Z,11Z,13E,17Z)-15-oxoicosa-5,8,11,13,17-pentaenoic acid.
6. The composition of claim 2 , wherein the (5Z,8Z,11Z,13E,17Z)-15-oxoicosa-5,8,11,13,17-pentaenoic acid is in a free acid form, an esterified form, or an ethyl ester form.
7. The composition of claim 5 , wherein the composition is formulated for treating liver fibrosis.
8. The composition of claim 7 , wherein the liver fibrosis is non-alcoholic fatty liver disease (NAFLD).
9. The composition of claim 5 , wherein (5Z,8Z,11Z,13E,17Z)-15-oxoicosa-5,8,11,13,17-pentaenoic acid is the only active ingredient in the pharmaceutical composition.
10. The composition of claim 5 , wherein the pharmaceutical composition is formulated for oral administration.
11. The composition of claim 4 , wherein the composition is a pharmaceutical composition comprising about 0.1 g to about 4 g of (8Z,11Z,13E)-15-oxoicosa-8,11,13-trienoic acid.
12. The composition of claim 4 , wherein the (8Z,11Z,13E)-15-oxoicosa-8,11,13-trienoic acid is in a free acid form, an esterified form, or an ethyl ester form.
13. The composition of claim 12 , wherein the pharmaceutical composition is formulated for treating liver fibrosis.
14. The composition of claim 13 , wherein the liver fibrosis is non-alcoholic fatty liver disease (NAFLD).
15. The composition of claim 11 , wherein the (8Z,11Z,13E)-15-oxoicosa-8,11,13-trienoic acid is the only active ingredient in the pharmaceutical composition.
16. The composition of claim 11 , wherein the pharmaceutical composition is formulated for oral administration.
17. A composition comprising (5Z,8Z,11Z,13E,17Z)-15-oxoicosa-5,8,11,13,17-pentaenoic acid and (8Z,11Z,13E)-15-oxoicosa-8,11,13-trienoic acid.
18. The composition of claim 17 , wherein the composition is a pharmaceutical composition.
19. The composition of claim 18 , wherein either the (5Z,8Z,11Z,13E,17Z)-15-oxoicosa-5,8,11,13,17-pentaenoic acid or the (8Z,11Z,13E)-15-oxoicosa-8,11,13-trienoic acid is in a free acid form, an esterified form, or an ethyl ester form.
20. The composition of claim 19 , wherein the composition is formulated for treating liver fibrosis.